Austin Rayford

Statistics

Publications

Citations

223

H-Index

Active since

2020

Affiliations

BerGenBio (Norway)(Current)

University of Bergen

Haukeland University Hospital

Université Paris-Saclay

Southwestern Medical Center

Austin Rayford is an author at BerGenBio (Norway) specializing in oncology, immune checkpoint resistance, and resistance to immune checkpoint inhibition.

ORCID

Publications per year

2020–2024

Publications

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Huiyu Li, Zhida Liu, Longchao Liu et al. · Cell Reports Medicine · 2022 · 94 citations · Full text

Life Sciences, Immunology, Oncology +17

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells

Maria L. Lotsberg, Katarzyna Wnuk-Lipińska, Stéphane Terry et al. · Journal of Thoracic Oncology · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacology +17

Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models

Maria L. Lotsberg, Gro Vatne Røsland, Austin Rayford et al. · Frontiers in Oncology · 2022 · 20 citations · Full text

Medicine, Cancer Biology, Cell Biology +17

AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy

Austin Rayford, Fabian Gärtner, Maria Ramnefjell et al. · Frontiers in Immunology · 2024 · 16 citations · Full text

Medicine, Cancer Biology, Oncology +17

1–4 of 4